Anti-SARS-CoV-2 equine immunoglobulin fragments

N/A

Report date: 2024/11/07 13:31:40

Base Information

Drug NameAnti-SARS-CoV-2 equine immunoglobulin fragments
Drug Alias NameAnti-SARS-CoV-2 Equine Immunoglobulin F(ab')2 Fragments (INOSARS)
ClassificationBiologics > Protein drugs > Immunoglobulin
Mechanisms of ActionImmunomodulatorsVirus internalization inhibitorsVirus replication inhibitors
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMexico
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesHospital San Jose Tec De Monterrey
China Registration ClassN/A

Develop Information

Active CompaniesHospital San Jose Tec De Monterrey
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A